All In Biotech

Drug Trial Radar · NCT04107168

Microbiome Immunotherapy Toxicity and Response Evaluation

An Observational Study to Evaluate the Microbiome as a Biomarker of Efficacy and Toxicity in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy

Last checked: Nov 20, 2026Latest source record: Feb 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,800

Planned (sponsor's estimate)

Start

Jul 8, 2020

Primary completion

Jul 8, 2024

Study completion Jul 8, 2025

Sponsor

Lead sponsor
CCTU- Cancer ThemeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Microbiotica Ltd
First posted
Sep 27, 2019

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer.

Conditions

  • Melanoma
  • Renal Cancer
  • Lung Cancer

Interventions

  • NivolumabDrug

    A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).

  • PembrolizumabDrug

    A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.

  • IpilimumabDrug

    A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).

  • DurvalumabDrug

    A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).

  • TremelimumabDrug

    A fully human monoclonal antibody raised to target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).

  • AtezolizumabDrug

    A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).

  • BevacizumabDrug

    A humanised IgG1 monoclonal antibody raised to target vascular endothelial growth factor (VEGF).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Can the microbiome signature predict progression-free survival (PFS) of 1 year or greaterTime frame: Minimum 1 year PFS

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Royal United Hospitals Bath NHS Foundation Trust

    Bath, United Kingdom · Recruiting

  • University Hospitals Dorest NHS Foundation Trust

    Bournemouth, United Kingdom · Recruiting

  • University Hospitals Bristol NHS Foundation Trust

    Bristol, United Kingdom · Recruiting

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom · Recruiting

  • Velindre University NHS Trust

    Cardiff, United Kingdom · Recruiting

  • Western General Hospital

    Edinburgh, United Kingdom · Recruiting

  • The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust

    Kings Lynn, United Kingdom · Recruiting

  • University Hospitals of Leicester NHS Foundation Trust

    Leicester, United Kingdom · Recruiting

  • Norfolk and Norwich University Hospitals NHS Foundation Trust

    Norwich, United Kingdom · Recruiting

  • Sheffield Teaching Hospitals NHS Foundation Trust

    Sheffield, United Kingdom · Recruiting

  • University Hospital Southampton NHS Foundation Trust

    Southampton, United Kingdom · Recruiting

  • Somerset NHS Foundation Trust

    Taunton, United Kingdom · Recruiting

  • Royal Cornwall Hospitals NHS Trust

    Truro, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.